Managing Bone Pain While Taking Hormone Therapy

Tamoxifen and other hormone therapy drugs can cause bone and joint pain as a side effect. The pain can have a severe impact on quality of life for some who take these drugs as treatment for hormone receptor-positive breast cancer.

Fortunately, non-steroidal anti-inflammatory medications (NSAIDs) and other treatments can help improve this side effect. Managing bone pain and other side effects of hormone therapy is critical to help you stay on it for the prescribed five years or more.

This article looks at bone pain as a side effect of hormone therapy for breast cancer, and how you can manage this pain long-term.

Senior woman rubbing her shoulder
Jose Luis Pelaez Inc / Getty Images

Hormone Therapy and Bone and Joint Pain

Bone and joint pain, which is a major complaint of many taking a hormone therapy, is a side effect that can cause problems in everyday living.

Given that hormone therapy is usually prescribed for five years and possibly longer, it's important to find ways to reduce the impact of bone and joint pain on mobility, work-related tasks, and routine activities of daily living. When women and men on hormone therapy cannot get relief from their bone and joint pain, many consider quitting treatment, and some do. 

Arimidex vs. Tamoxifen

Arimidex (anastrozole) and tamoxifen are two hormone therapy drugs prescribed to people who have hormone receptor-positive breast cancer. Some studies have found Arimidex to be more effective than tamoxifen. However, bone and joint pain were reported more frequently on Arimidex than on tamoxifen. Arimidex is also associated with a higher risk of fractures.

For many women, the daily occurrence of bone and joint pain is their biggest complaint. The severity of this pain and its impact on daily living causes some women on Arimidex to stop taking it.

Most women experiencing bone and joint pain report having stiffness and pain upon awakening in their hands, hips, back, knees, feet, and shoulders. These people say the pain makes it difficult to perform daily activities and work-related tasks.

Joint pain often occurs in the knees, back, ankles, and feet as well as the hips. Carpal tunnel syndrome was a frequent diagnosis as well.

Managing Bone Pain

Despite the pain, many were able to get pain relief from taking non-steroidal anti-inflammatory drugs.

Some people recommend taking dietary supplements such as vitamins, glucosamine and chondroitin, vitamin D, and omega fish oils. However, research hasn't shown that this is effective.

Acupuncture has been demonstrated to help relieve bone pain. Women taking Arimidex or another aromatase inhibitor are encouraged to regularly participate in a weight-bearing exercise.

Given that aromatase inhibitors are known to cause muscle and joint pain, it is important to talk to your oncology team if you develop this side effect. Your team will want to evaluate the level of your pain, refer you for a bone density test if you haven't had one, and recommend exercises, activities, and possible use of medication to reduce your pain level.

The results of a small study indicate that survivors taking an aromatase inhibitor who participated regularly in a course of exercise for a year had about a 30% decrease in their worst pain.

They also experienced a lessening in the severity of their pain. These reductions in pain resulted in an increased ability to perform routine activities of daily living. Women in the study who didn’t follow an exercise program for a year experienced a 3% increase in pain and in the severity of their pain.

Hormone Therapy Reduces Recurrence Risk

The importance of using (and continuing) hormone therapy despite bone pain can't be overestimated in those who have had early stage breast cancer. These medications certainly reduce recurrence risk (by around half) early on, but what many people are less aware of is that they reduce the risk of late recurrence.

Unlike popular opinion that equates surviving five years with a "cure," we now know that the risk of recurrence in women who have had estrogen-receptor positive breast cancer does not drop off at 5 years. In fact, a person's risk of having the cancer return is constant from year 5 to year 20 following the diagnosis. Overall, an estrogen-receptor positive tumor is more likely to recur after 5 years than in the first 5 years.

Chemotherapy, while it reduces early recurrences significantly, does not appear to affect the risk of late recurrence. In contrast, hormone therapy can reduce the risk of these late recurrences, and the decreased risk lasts even after the medication has been discontinued.

Other Side Effects 

Tamoxifen and aromatase inhibitors are both known to share similar side effects including:

  • Hot flashes and night sweats
  • Loss of sex drive
  • Vaginal discharge
  • Vaginal dryness or itching
  • Weight gain
  • Sleep difficulties
  • Mood changes

Tamoxifen may increase the risk of blood clots and uncommonly, uterine cancer. Aromatase inhibitors can lead to bone loss (and people should consider having a bone density test done at the start of therapy). Since tamoxifen has anti-estrogen effects on breast cells but estrogen-like effects on bone, it doesn't lead to bone loss like aromatase inhibitors. Other very uncommon side effects may occur as well.


Tamoxifen and Arimidex are two types of hormone therapy prescribed to treat breast cancer. Many people continue to take these medications long-term to help prevent cancer recurrence.

One of the most common side effects of hormone therapy is bone and joint pain. Because it is important to stay on these medications for as long as prescribed, you need to find good ways to manage this symptom. For some people, it is enough to take NSAID medications.

Other studies have found that acupuncture and exercise may help you manage your pain. Talk to your oncologist about other possible treatments such as aromatase inhibitors. 

A Word from Verywell

Hormone therapy works and it does reduce the incidence of recurrence. Arimidex is being prescribed more and more often than tamoxifen since it has proven to be more successful than tamoxifen in preventing a recurrence.

If you are taking an aromatase inhibitor and are experiencing bone and joint pain, share what you are experiencing with your oncology team. You may be advised to participate in an organized exercise class in your community or join a walking group. Your medical oncologist can advise you about which pain relievers you can safely take, as even over the counter medications have side effects.

11 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Hyder T, Marino CC, Ahmad S, Nasrazadani A, Brufsky AM. Aromatase inhibitor-associated musculoskeletal syndrome: understanding mechanisms and management. Front Endocrinol. 2021;12:713700. doi:10.3389/fendo.2021.713700

  2. MD Anderson Cancer Center. How does hormone therapy for breast cancer work?

  3. Yang Y, Pan W, Tang X, Wu S, Sun X. A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer. Oncotarget. 2017;8(29):48362-48374. doi:10.18632/oncotarget.16466

  4. Tseng OL, Spinelli JJ, Gotay CC, Ho WY, McBride ML, Dawes MG. Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis. Ther Adv Musculoskelet Dis. 2018;10(4):71-90. doi:10.1177/1759720X18759291

  5. Yang GS, Kim HJ, Griffith KA, Zhu S, Dorsey SG, Renn CL. Interventions for the treatment of aromatase inhibitor–associated arthralgia in breast cancer survivors: A systematic review and meta-analysis. Cancer Nurs. 2017;40(4):E26-41. doi:10.1097/NCC.0000000000000409

  6. Irwin ML, Cartmel B, Gross CP, et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol. 2015;33(10):1104-11.  doi:10.1200/JCO.2014.57.1547

  7. Pan H, Gray R, Braybrooke, J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 tearsN Engl J Med. 2017;377:1836-1846. doi:10.1056/NEJMoa1701830

  8. Taylor CE, Meisel JL. Management of breast cancer therapy-related sexual dysfunction. Oncology (Williston Park, NY). 2017;31(10):726-9.

  9. Lester J, Pahouja G, Andersen B, Lustberg M. Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue. J Pers Med. 2015;5(2):50-66. doi:10.3390/jpm5020050

  10. Bhave MA, Speth KA, Kidwell KM, et al. Effect of aromatase inhibitor therapy on sleep and activity patterns in early-stage breast cancer. Clin Breast Cancer. 2018;18(2):168-174.e2. doi:10.1016/j.clbc.2017.12.012

  11. American Cancer Society. Tamoxifen and Raloxifene for lowering breast cancer risk.

By Jean Campbell, MS
Jean Campbell, MS, is a breast cancer survivor and advocate, and the founding director of the American Cancer Society Patient Navigator Program.